Skip to main content
SpringerLink
Log in

Effector mechanism of human monocyte-mediated cytotoxicity: role of a new tumor cytotoxic factor distinct from interleukin 1 and tumor necrosis factorα

  • Published:
Biotherapy

Abstract

Human blood monocytes activated to the tumoricidal state were previously found to release a factor(s) responsible for tumor cell killing. The activity of the tumor cytotoxic factor(s) (TCF) was determined by release assay of radioactivity from human A375 melanoma cells. On fractionation of the supernatant of activated monocytes by Ultrogel AcA34 and TSK-G3000SW gel chromatographies two major peaks of the material with TCF activity with MWs of 30,000 and 15,000, called TCF-I and TCF-11, respectively were obtained. TCF-II could be neutralized by polyclonal anti-IL-1β antiserum, but anti-IL-1α antiserum did not neutralize either factor. TCF-I was separated by ampholine column electrofocusing into three major fractions with TCF activity at pI 5, 6 and 6.8, named TCF-1α, TCF-1β and TCF-1γ, respectively. The cytotoxic and IL-1 activities of TCF-1α were neutralized by anti-IL-1α serum, whereas those of TCF-1β and TCF-1γ were not completely neutralized by anti-IL-1α or anti-IL-1β antiserum. On DEAE ion-exchange chromatography (TSK DEAE 5PW) TCF-Iβ gave two peaks with TCF activity (TCF-Iβ1 and TCF-Iβ2). TCF-Iβ1 was slightly neutralized by anti-TNFα antibody, but TCF-Iβ2 was not affected by antisera against IL-1α and IL-1β, or anti-TNFα antibody, thus ruling out the possibility that tumor necrosis factor (TNFα) might be involved in tumor cell killing mediated by TCF-Iβ2. These results indicate that human monocyte-mediated cytotoxicity against human A375 melanoma cells is mediated in part by a tumor cytotoxic factor (TCF; MW, 30,000; pI 6), differing from IL-1 and TNFα.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fidler IJ. Macrophages and metastases — a biological approach to cancer therapy. Presidential Address. Cancer Res 1985; 45: 4714.

    Google Scholar 

  2. Sone S. Role of alveolar macrophages in pulmonary neoplasias. Biochim Biophys Acta 1986; 823: 227.

    Google Scholar 

  3. Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 1984; 2: 937.

    Google Scholar 

  4. Jett JR, Mantovani A, Herberman RB. Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol 1980; 54: 425.

    Google Scholar 

  5. Sone S, Tsubara E. Human alveolar macrophages: Potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol 1982; 129: 1313.

    Google Scholar 

  6. Utsugi T, Sone S. Comparative analysis of the priming effect of human interferon-γ, α andβ on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes. J Immunol 1986; 136: 1117.

    Google Scholar 

  7. Hibbs JR Jr. Heterocytolysis by macrophages activated byBacillus Calmette-Guerin: Lysosome exocytosis into tumor cells. Science 1974; 184: 468.

    Google Scholar 

  8. Bucana CD, Hoyer LC, Schroit AJ, Kleinerman E, Fidler IJ. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am J Pathol 1983; 112: 101.

    Google Scholar 

  9. Nathan CF. Secretory products of macrophages. J Clin Invest. 1987; 79: 319.

    Google Scholar 

  10. Nathan CF, Silverstein SC, Brukner LH, Cohn ZA. Extra-cellular cytolysis by activated macophages and granulocytes: Hydrogen superoxide as a mediator of cytotoxicity. J Exp Med 1979; 149: 100.

    Google Scholar 

  11. Adams DO, Kad KJ, Farb R, Pizzo SV. Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol 1980; 124: 293.

    Google Scholar 

  12. Ferluga J, Schorlemmer HU, Baptista LC, Allison AC. Production of the complement cleavage product, C3a, by activated macrophages and its tumorlytic effects. Clin Exp Immunol 1978; 31: 512.

    Google Scholar 

  13. Currie GA. Activated macrophages kill tumour cells by releasing arginase. Nature 1978; 273: 758.

    Google Scholar 

  14. Reed WP, Lucas ZJ. Cytotoxic activity of lymphocytes. V. Role of soluble toxin in macrophage inhibited culture of tumor cells. J Immunol 1975; 115: 395.

    Google Scholar 

  15. Hammerström, J. Soluble cytostatic factor(s) released from human macrophages. Scand J Immunol 1982; 15: 311.

    Google Scholar 

  16. Sone S, Tachibana K, Ishii K, Ogawara M, Tsubura E. Production of a tumor cytolytic factor(s) by activated human alveolar macrophages and its action. Cancer Res 1984; 44: 646.

    Google Scholar 

  17. Sone S, Lopez-Berestein G, Fidler IJ. Kinetics and function of tumor cytotoxic factor(s) produced by human blood monocytes activated to the tumoricidal state. J Natl Cancer Inst 1985; 74: 583.

    Google Scholar 

  18. Klostergaad J, Foster WA, Hamilton DA, Turpin J, Lopez-Berestein G. Effector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: Biochemical, functional, and serological characterization of cytotoxins produced by peripheral blood monocytes isolated by counterflow elutriation. Cancer Res 1986; 46: 2871.

    Google Scholar 

  19. Armstron CA, Klostergaad J, Granger GA. Isolation and initial characterization of tumoricidal monokine(s) from the human monocytic leukemia cell line THP-1. J Natl Cancer Inst 1985; 74: 1.

    Google Scholar 

  20. Taniyama T, Yoshida K, Furuta T. Demonstration of a novel tumor-killing factor secreted from human macrophage-monocyte hybridomas. J Immunol 1988; 141: 4061.

    Google Scholar 

  21. Ziegler-Heitbrook HW, Moller A, Linke RP, Haas JG, Rieber EP, Rietmuller G. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res 1986; 46: 5947.

    Google Scholar 

  22. Feinman R, Henriksen-Destefano D, Tsujimoto M, Vilcek J. Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 1987; 138: 635–640.

    Google Scholar 

  23. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin I is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962.

    Google Scholar 

  24. Lachman LB, Dinarello CA, Llansa ND, Fidler IJ. Natural and recombinant human interleukin 1-β is cytotoxic for human melanoma cells. J Immunol 1986; 136: 3098.

    Google Scholar 

  25. Hirai Y, Masui Y, Nakai S, Kikumoto Y, Nishida T, Honjo Y. Interleukin 1: cDNA cloning, production and biological activities of human interleukin 1. Gann Monograph on Cancer Res. 1988; 34: 155.

    Google Scholar 

  26. Sone S, Mutsuura S, Ishii K, Shirahama T, Tsubura E.In vitro cytotoxicity to various human tumor cell lines of a human cytotoxic factor(s) produced by human alveolar macrophages. Gann 1984; 75: 920.

    Google Scholar 

  27. Tandon P, Utsugi T, Sone S. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide. Cancer Res 1986; 46: 5039.

    Google Scholar 

  28. Okubo A, Sone S, Tanaka M, Ogura T. Membrane-associated interleukin-la as a mediator of tumor cell killing by human blood monocytes fixed with paraformaldehyde. Cancer Res 1989; 49: 265.

    Google Scholar 

  29. Ichinose Y, Bakouche O, Tsao JY, Fidler IJ. Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both. J Immunol 1988; 141: 512.

    Google Scholar 

  30. Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA, Old LJ. Purification and characterization of a human tumor necrosis factor from the LuKII cell line. Proc Natl Acad Sci USA 1985; 82: 6637.

    Google Scholar 

  31. atsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL I from monocytes by trypsin and plasmin. J Immunol 1986; 136: 2883.

    Google Scholar 

  32. Fleit HB, Rabinovitch M. Production of interferon byin vitro derived bone marrow macrophages. Cell Immunol 1981; 57: 495.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The 3rd Department of Internal Medicine, The University of Tokushima School of Medicine, 770, Kuramoto-cho, Tokushima, Japan

    Saburo Sone, Masanobu Munekata, Makoto Tanaka, Teruhiro Utsugi & Takeshi Ogura

Authors
  1. Saburo Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masanobu Munekata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruhiro Utsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeshi Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sone, S., Munekata, M., Tanaka, M. et al. Effector mechanism of human monocyte-mediated cytotoxicity: role of a new tumor cytotoxic factor distinct from interleukin 1 and tumor necrosis factorα . Biotherapy 1, 233–243 (1989). https://doi.org/10.1007/BF02170892

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02170892

Key words

Search

Navigation